|Bid||0.0000 x 0|
|Ask||0.0000 x 0|
|Day's Range||0.0096 - 0.0115|
|52 Week Range||0.0030 - 0.1539|
|Beta (5Y Monthly)||0.80|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
OWC Pharmaceutical Research Corp. (OTCQB: OWCP) ("OWC"), represented by its wholly-owned subsidiary, One World Cannabis Ltd., a company organized and existing under the laws of Israel ("OWC-Israel"), announced that, on December 9, 2019, the United States Patent and Trademark Office issued a Notice of Allowance indicating that OWC Israel's Patent Application No. 15/629,230 directed to cannabis based extracts and topical formulations for use in skin disorders, is allowed for issuance as a patent. The allowed patent application, which indicates a unique modality of treatment, covers a method of treating or inhibiting an inflammatory skin disease in a human in need thereof comprising topically administering to the human a therapeutically effective amount of a pharmaceutical composition comprising carrier formulations described in the claims and cannabis oil comprising cannabidiol and tetrahydrocannabinol, wherein the inflammatory skin disease is selected from a large group of skin conditions, including but not limited to psoriasis.
The new relationship will provide market access to OWC's technologies and will accelerate STENOCAREs long term strategy to supplement its high quality generic medical cannabis products with differentiated products that are formulated to target specific patient groups suffering from specific conditions. The companies wish to cooperate in order to jointly develop and promote the sale and distribution of products within STENOCARE's current core markets (Denmark, Ireland) and potentially in new territories to be targeted by STENOCARE. OWC will provide its expertise in medical research and clinical trials for cannabis-based novel therapeutic products and treatments, backed by its extensive Intellectual Property Portfolio.
RAMAT GAN , Israel , Oct. 7, 2019 /PRNewswire/ -- OWC Pharmaceutical Research Corp. (OTCQB: OWCP), a developer of cannabinoid-based therapies targeting a variety of different medical conditions and disorders, ...
RAMET GAN, Israel , Aug. 5, 2019 /PRNewswire/ -- OWC Pharmaceuticals Research Corp. ("OWC") (OTCQB: OWCP) announced that, on July 18, 2019 , it received long-awaited approval from the Israeli ...